Aristotle Capital Management’s Rentokil RTO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$56.5M Sell
1,796,236
-20,261
-1% -$638K 0.12% 98
2025
Q4
$53.5M Sell
1,816,497
-83,479
-4% -$2.32M 0.11% 101
2025
Q3
$48M Sell
1,899,976
-17,355
-0.9% -$423K 0.09% 110
2025
Q2
$46M Buy
1,917,331
+31,703
+2% +$735K 0.09% 113
2025
Q1
$43.2M Sell
1,885,628
-40,474
-2% -$977K 0.09% 110
2024
Q4
$48.8M Sell
1,926,102
-21,805
-1% -$553K 0.09% 102
2024
Q3
$48.6M Sell
1,947,907
-102,351
-5% -$3.03M 0.09% 107
2024
Q2
$60.8M Buy
2,050,258
+30,422
+2% +$844K 0.12% 95
2024
Q1
$60.9M Buy
2,019,836
+34,837
+2% +$967K 0.11% 96
2023
Q4
$56.8M Sell
1,984,999
-98,166
-5% -$2.88M 0.11% 100
2023
Q3
$77.2M Buy
2,083,165
+5,105
+0.2% +$195K 0.17% 70
2023
Q2
$81.1M Buy
2,078,060
+35,502
+2% +$1.39M 0.16% 66
2023
Q1
$74.6M Buy
2,042,558
+118,631
+6% +$3.74M 0.16% 65
2022
Q4
$59.3M Buy
+1,923,927
New +$59.7M 0.13% 83

Other funds holding RTO

Aristotle Capital Management's RTO Position: Q1 2026 in Review

Aristotle Capital Management reduced its Rentokil (RTO) stake by 1.1% in Q1 2026, selling an estimated $638K and leaving 1,796,236 shares worth $56.5M. The position accounts for 0.12% of the portfolio, ranked #98.

Aristotle Capital Management first reported a position in RTO in Q4 2022 and has held it in 14 quarters since. The position peaked at $81.1M in Q2 2023. 282 funds tracked by Wall St. Rank hold RTO as of Q1 2026.

  • Aristotle Capital Management held 1,796,236 shares of Rentokil worth $56.5M as of Q1 2026.
  • Aristotle Capital Management sold 20,261 Rentokil shares in Q1 2026, an estimated $638K.
  • Rentokil made up 0.12% of Aristotle Capital Management's portfolio in Q1 2026, its #98 holding.
  • Aristotle Capital Management first reported a position in Rentokil in Q4 2022 and has held it in 14 quarters since.
  • Aristotle Capital Management's Rentokil position peaked at $81.1M in Q2 2023.
  • 282 funds tracked by Wall St. Rank held Rentokil as of Q1 2026.

Based on Aristotle Capital Management's 13F filing for Q1 2026, filed 15 May 2026.